Purpose A high interindividual variability is observed in the pharmacokinetics of clopidogrel,
a widely used antiplatelet drug. In the present study, a joint parent-metabolite population …

Abstract Background and Objectives Resistance to the antiplatelet treatment with clopidogrel
has both genetic and non-genetic causes. Polymorphic variants of cytochrome P450 3A4 …

Treatment response to clopidogrel is associated with CYP2C19 activity through the
formation of the active H4 metabolite. The aims of this study were to develop a …

Purpose Response to clopidogrel varies widely with nonresponse rates ranging from 4% to
30%. A reduced function of the gene variant of the CYP2C19 has been associated with …

Clopidogrel is an antiplatelet drug used to reduce the risk of acute coronary syndrome and
stroke. It is converted by CYP2C19 to its active metabolite; therefore, poor metabolizers …

Clopidogrel (Plavix®), is a widely used antiplatelet agent, which shows high inter-individual
variability in treatment response in patients following the standard dosing regimen. In this …

We evaluated the effect of the CYP2C19 genotype on the pharmacokinetics and
pharmacodynamcis of clopidogrel. Twenty‐four subjects were divided into three groups on …

Clopidogrel is a prodrug that needs to be converted to its active metabolite (clopi-H4) in two
sequential cytochrome P450 (P450)-dependent steps. In the present study, a dynamic …

Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive
prodrug that needs to be converted to an active metabolite in two sequential metabolic …

Aim The primary objective of the present study was to evaluate the pharmacokinetic and
pharmacodynamic interactions between clopidogrel and cilostazol in relation to the …